TY - JOUR T1 - Identification of Lifelines participants at high risk for development of rheumatoid arthritis JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e43 LP - e43 DO - 10.1136/annrheumdis-2017-211256 VL - 76 IS - 11 AU - S Arends AU - L A Trouw AU - R E M Toes AU - A van Zanten AU - C Roozendaal AU - P C Limburg AU - H Bootsma AU - E Brouwer Y1 - 2017/11/01 UR - http://ard.bmj.com/content/76/11/e43.abstract N2 - We would like to thank Michael Mahler1 for his letter, ‘Population-based screening for anticitrullinated protein antibodies (ACPA): A step in the pathway to the prevention of rheumatoid arthritis?’ In his letter, Dr Mahler makes a plea to analyse and define reliable biomarkers to identify subjects who are on the trajectory to develop rheumatoid arthritis (RA). We agree with this notion of Dr Mahler as current efforts are increasingly focusing on the possibility to install early preclinical treatment to prevent progression to RA. For example, several randomised placebo-controlled trials (RCTs) have been initiated recently. These clinical trials will investigate the therapeutic potential of several immunomodulatory agents such as rituximab (PRAIRI study: NTR No. 1969), abatacept (APIPPRA study: ISRCTN No. 46017566 and ARIAA study: EudraCT … ER -